Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 4/20 | 0.44 |
| ▸ | HEXA | P06865 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.31 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15521171 | 0.94 | OGA (0.45) | OGAHEXACYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL15521173 | 0.94 | OGA (0.45) | OGAHEXACYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL15521326 | 0.94 | OGA (0.45) | OGAHEXACYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL8280849 | 0.86 | OGA (0.41) | OGAHEXACYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL25680916 | 0.82 | OGA (0.41) | OGACYP2C9CYP2C19ALDH1A1SMN1; SMN2 | |
| SCHEMBL15980408 | 0.78 | OGA (0.38) | OGACYP2C9CYP2C19ALDH1A1SMN1; SMN2 | |
| SCHEMBL14426718 | 0.77 | OGA (0.44) | OGAHEXACYP2C9CYP2C19GAA | |
| SCHEMBL3260691 | 0.76 | OGA (0.35) | OGACYP2C9CYP2C19ALDH1A1HPSE | |
| SCHEMBL3260696 | 0.76 | OGA (0.35) | OGACYP2C9CYP2C19ALDH1A1HPSE | |
| SCHEMBL3260689 | 0.76 | OGA (0.35) | OGACYP2C9CYP2C19ALDH1A1HPSE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197471-A1 | Treatment of degenerative cartilage conditions in a mammal with Glycosidasc Inhibitors | OPTIMER PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197471-A1 | Treatment of degenerative cartilage conditions in a mammal with Glycosidasc Inhibitors | MMP1, MMP13, MMP3 | OGA 77/4885HEXA 43/4885CYP2C9 4601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.